IP Library Granted Patent US 12,377,059
Granted Patent B2
US 12,377,059 · App. 18/353,251 · Granted Aug 5, 2025

Complexes comprising collagen peptides and curcuminoids and compositions thereof

Inventors: Krishnakumar Illathu Madhavamenon (Kerala, IN); Balu Paulose Maliakel (Kerala, IN)
Assignee: AKAY NATURAL INGREDIENTS PRIVATE LIMITED
A61K31/12A61K9/08A61K9/1075A61K9/19A61K9/20A61K9/48A61K36/73A61K36/9066A61K38/014A61K38/39A61K47/10A61K47/14A61K47/26A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,059
App. No.
18/353,251
Granted
Aug 5, 2025
Kind
B2
Abstract

Formulations comprising complexes of peptides with hydrophobic bioactive molecules are described herein. The invention more specifically relates to collagen peptide and curcuminoid complexes and compositions comprising the complexes. The compositions and formulations comprising the protein hydrolysate peptide-hydrophobic bioactive molecule complexes are water-soluble, stable at physiological and acidic pH, synergistically enhance the systemic bioavailability of the biomolecules and peptides, and are capable of delivering a high therapeutically effective amount of the bioactive molecules via oral route. The compositions and formulations comprising the collagen peptide-curcuminoid complexes provide significantly high levels of bioavailable curcuminoids that are water soluble and stable at physiological and acidic pH along with significant anti-inflammatory effects offered by collagen peptides. The invention further provides a process for preparing the peptide-bioactive molecule complexes, compositions and oral formulations comprising the collagen peptide-curcuminoid complex.

Claims (19)

1. A method of preparing water soluble pharmaceutical composition, comprising the steps of:

a. micronising hydrophobic bioactive molecules to form micronized hydrophobic bioactive molecules;

b. emulsifying the micronized hydrophobic bioactive molecules by homogenisation with an emulsifier with phosphatidylcholines to form emulsified hydrophobic bioactive molecules;

c. dissolving collagen peptides in water at a concentration range of 20 to 95% to form dissolved collagen peptides;

d. sonicating the emulsified hydrophobic bioactive molecules from step (b) with the dissolved collagen peptides from step (c) to form a complex of hydrophobic bioactive molecules;

e. encapsulating the complex from step (d) by ultrasound mediated homogenisation to form encapsulated complex of hydrophobic bioactive molecules; and

f. drying the encapsulated complex from step (e) by spray drying or freeze drying to form the water soluble pharmaceutical composition;

wherein said collagen peptides form an amorphous, nano-sized non-covalent complex with the hydrophobic bioactive molecules and encapsulated in the collagen peptide matrix, and wherein the hydrophobic bioactive molecules are selected from the group consisting of curcuminoids, gingerol, flavonoids, stilbenes, carotenoids, terpenes, terpenoids, and chlorophyll.

2. The method of claim 1 , wherein the emulsifier is lecithin.

3. A water soluble pharmaceutical composition prepared by the method of claim 1 .

4. A water soluble pharmaceutical composition of claim 3 , wherein the hydrophobic bioactive molecules are present at a concentration in the range of from 1 to 25% of the composition.

5. The water soluble pharmaceutical composition of claim 3 , wherein the collagen peptides are present at a concentration in the range of from 10 to 90% of the composition.

6. The water soluble pharmaceutical composition of claim 3 , wherein the hydrophobic bioactive molecules exhibit enhanced solubility and stability as compared to unformulated hydrophobic bioactive molecules.

7. The water soluble pharmaceutical composition of claim 3 , wherein the hydrophobic bioactive molecules exhibit an increased bioavailability, increased absorption and a longer half-life following an oral administration to a subject, as compared to unformulated hydrophobic bioactive molecules.

8. The water soluble pharmaceutical composition of claim 3 , wherein the hydrophobic bioactive molecules exhibit an increased cellular permeability, as compared to unformulated hydrophobic bioactive molecules.

9. The water soluble pharmaceutical composition of claim 3 , wherein the water soluble pharmaceutical composition exhibits an enhanced anti-inflammatory effect following an oral administration to a subject, as compared to unformulated hydrophobic bioactive molecules.

10. The water soluble pharmaceutical composition of claim 3 , wherein the water soluble pharmaceutical composition is prepared for oral administration in a form of capsules, tablets, softgels, beadlets, liquid solution, liquid suspension, liquid emulsion, or powder sachets for enhanced bioavailability of the hydrophobic bioactive molecules.

11. The water soluble pharmaceutical composition of claim 3 , wherein the water soluble pharmaceutical composition is prepared for oral administration at a dose of from 100 to 500 mg/dose in the form of tablets, capsules or softgel.

12. The water soluble pharmaceutical composition of claim 3 , wherein the water soluble pharmaceutical composition is prepared for oral administration at a dose of 1000 mg to 5000 mg per sachet, once or twice a day, to deliver a minimum of 100 mg to 500 mg of hydrophobic bioactive molecules and 1 g to 10 g of collagen peptides/dosage/day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2023
From: MADHAVAMENON, KRISHNAKUMAR ILLATHU; MALIAKEL, BALU PAULOSE
To: AKAY FLAVOURS & AROMATICS PVT, LTD
Reel/Frame 064298/0372 →
CHANGE OF NAME Recorded Jul 18, 2023
From: AKAY FLAVOURS & AROMATICS PVT, LTD.
To: AKAY NATURAL INGREDIENTS PRIVATE LIMITED
Reel/Frame 064306/0225 →
Priority Claims (1)
IN 201941003319 · Jan 28, 2019 · national
Continuity (2)
Continuation 16773494 · Jan 27, 2020
Related Publication 20240050381A1 · Feb 15, 2024
References Cited (11)
US 20100179103A1 · Desai · 2010 [cited by applicant]
WO WO2010010431A1 · 2010 [cited by applicant]
WO WO2010013224A2 · 2010 [cited by examiner]
WO WO2015025263A1 · 2015 [cited by examiner]
Gomez-Estaca et al., Improving antioxidant and antimicrobial properties of curcumin by means of encapsulation in gelatin through electrohydrodynamic atomization, Food Hydrocolloids, 2017, vol. 70: 313-320. [cited by examiner]
Comblain et al., Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract Synergically Inhibit Inflammatory and Catabolic Mediator's Synthesis by Normal Bovine and Osteoarthritic Human Chondrocytes in Monolayer, … [cited by examiner]
Gómez-Estaca J., et al., “Improving antioxidant and antimicrobial properties of curcumin by means of encapsulation in gelatin through electrohydrodynamic atomization,” [cited by applicant]
Jiang, Y. et al., “Self-emulsifying drug delivery system improves preventive effect of curcuminoids on chronic heart failure in rats,” [cited by applicant]
Comblain, F. et al., “Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract Synergically lnhibit Inflammatory and Catabolic Mediator's Synthesis by Normal Bovine and Osteoarthritic Human Chondrocytes in Monola… [cited by applicant]
Emea, “ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products,” [cited by applicant]
Louis, M.J., et al., “Two-Stage Supramolecular Self-AssembIy-Directed Collagen-Peptide-Decorated Liposomal Complexes of Curcumin Microspheres with Enhanced Solubility and Bioavailability,” [cited by applicant]